about
Full penetrance of Morgagni-Stewart-Morel syndrome in a 75-year-old woman: case report and review of the literature.The use of aspirin for primary and secondary prevention in venous thromboembolism and other cardiovascular disorders.Thromboembolic prevention in frail elderly patients with atrial fibrillation: a practical algorithm.Minimizing the risk of hemorrhagic stroke during anticoagulant therapy for atrial fibrillation.Vitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis.Direct Oral Anticoagulants and Their Use in Treatment and Secondary Prevention of Acute Symptomatic Venous Thromboembolism.Increasing incidence of non-valvular atrial fibrillation in the UK from 2001 to 2013.To treat or not to treat very elderly naïve patients with atrial fibrillation with vitamin K antagonists (VKA): results from the VENPAF cohort.Aspirin versus low-molecular-weight heparin after total hip arthroplasty.A new D-dimer cutoff in bedridden hospitalized elderly patients.Short- and long-term efficacy of cholinesterase inhibitors in older adults with alzheimer's disease and mixed dementia: results of a 21-month observational study.Nutritional and global indexes of progression in dementia: a 12-month prospective study.Monitoring Plasma Levels of Donepezil, 5-O-Desmethyl-Donepezil, 6-O-Desmethyl-Donepezil, and Donepezil-N-Oxide by a Novel HPLC Method in Patients With Alzheimer Disease.Primary thromboembolic prevention in multiple myeloma patients: An exploratory meta-analysis on aspirin useVitamin K antagonists' use and fracture risk: results from a systematic review and meta-analysis: replyPrescription of vitamin K inhibitors in low-risk patients with atrial fibrillationVTE primary prevention, including hospitalised medical and orthopaedic surgical patientsExcellence, quality and limitations of the NICE venous thromboembolism score tool: how can it be improved?Evidence suggests dabigatran is an effective and safe treatment for patients with VTE requiring early parenteral therapyNordic Walking and Walking in Parkinson's disease: a randomized single-blind controlled trial
P50
Q34531073-BD4B017C-BD21-4B29-8F14-3D0310704714Q38300796-3ABB27A2-A5B7-4BA2-85B9-ED7153216E74Q38354763-6B45CEF1-0059-4BE1-BEBF-F9B8752560A1Q38389058-3DA05E39-4A92-4A8B-B3C5-FB53F68A2970Q38548038-A6DEDB4D-3E95-4981-99D7-A2724C5CCFD9Q38578564-9E657C58-62B0-413A-9DCA-35642299482DQ40607580-0E5D9644-7073-4874-9575-CE0BE5C2CDDDQ41036908-ADFE7AE1-21AD-467F-8B7C-A2BFADE13056Q44499539-4ADBB408-2C22-49ED-9667-483DE4865542Q45398254-2056B4E9-C931-4C15-9B36-C3EA6C867A15Q50632904-84C6D0BF-29F0-4962-B517-62AEEA633146Q50745988-4F607E95-0A45-4DBA-9BF7-BF8D3FE3D5C3Q53367902-02001C3C-C1B0-43AB-9153-D0B5BB4E7EB6Q56768886-B3D2A1F7-6816-4354-9640-A5A5B5C90EC5Q60445849-195BEEAF-C188-4AE4-B414-984FF83DDF78Q85075314-580233F2-1557-4507-950B-2C0B1E0C7CABQ86993243-CFAD9491-8F87-46AB-A1A3-3087EE89235CQ87415298-FA1B0F31-27ED-4224-AF89-C59A4F60ED5BQ87891719-2A6E8CA5-7CCD-4757-AE34-3786D2304B4AQ96306619-F6E84B57-DDA6-46D8-9E21-E56B642AE68C
P50
description
researcher ORCID ID = 0000-0002-8974-0325
@en
name
Serena Granziera
@ast
Serena Granziera
@en
Serena Granziera
@es
Serena Granziera
@nl
type
label
Serena Granziera
@ast
Serena Granziera
@en
Serena Granziera
@es
Serena Granziera
@nl
prefLabel
Serena Granziera
@ast
Serena Granziera
@en
Serena Granziera
@es
Serena Granziera
@nl
P31
P496
0000-0002-8974-0325